AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-17. (Canceled)

18. (Currently Amended) A pharmaceutical composition comprising a compound of

formula (I) :



(I)

or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein:

R^2 is H or an optionally substituted C_{1-4} alkyl group; Y is either $-(CH_2)_n,-X-$, where n is 1 or 2 and X is 0, S, S (=O), or S $(=O)_2$ ~~, or NR^{N1}, where R^{N1} is selected from H or optionally substituted C_{1-4} alkyl, or Y is -C (=O) NR^{N2}-, where R^{N2} is selected from HI and optionally substituted C_{1-7} alkyl or C_{5-20} aryl~~;

R^3 is an optionally substituted C_6 aryl group linked to a further optionally substituted C_6 aryl group, wherein if both C_6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings;

A is a single bond or a C_{1-3} alkylene group; and

R^5 is either:

(i) carboxy;

(ii) a group of formula (II) :



(II)

; or

(iii) a group of formula (III) :



(III)

,

wherein R is optionally substituted C_{1-7} alkyl, C_{5-20} aryl or $NR^{N3}R^{N4}$, where R^{N3} and R^{N4} are independently selected from

optionally substituted C_{1-4} alkyl;

(iv) tetrazol-5-yl

19. (Currently Amended) A compound of formula (I) :



(I)

or a salt, solvate [[and]]or chemically protected form thereof,

wherein:

R^2 is H or an optionally substituted C_{1-4} alkyl group;

Y is either $-(CH_2)_n-X-$, where n is 1 or 2 and X is 0, S, S (=O), or $S(=O)_2$, ~~or NR^{N1}~~, ~~where R^{N1} is selected from H or optionally substituted C_{1-4} alkyl, or Y is $-C(=O)NR^{N2}-$, where R^{N2} is selected from H and optionally substituted C_{1-7} alkyl or C_{5-20} aryl~~;

R^3 is an optionally substituted C_6 aryl group linked to a further optionally substituted C_6 aryl group, wherein if both C_6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings;

A is a single bond or a C_{1-3} alkylene group; and

R^5 is either:

(i) carboxy;

(ii) a group of formula (II):



(II)

; or

(iii) a group of formula (III) :



(III)

wherein R is optionally substituted C_{1-7} alkyl, C_{5-20} aryl or $NR^{N3}R^{N4}$, where R^{N3} and R^{N4} are independently selected from optionally substituted C_{1-4} alkyl;

(iv) tetrazol-5-yl,

except that when R^2 is methyl, Y is $-CH_2-O-$ and R^5 is carboxy or C_{1-7} alkyl ester thereof, then R^3 is not::

(i)  ; or

(ii)  .

20. (Original) The compound according to claim 19, wherein R^2 is selected from H, methyl, CF_3 or iso-propyl.

21. (Original) The compound according to claim 20, wherein R^2 is methyl.

22. (Original) The compound according to claim 19, wherein Y is $-(CH_2)_n-X-$.

23. (Original) The compound according to claim 22, wherein n is 1.

24. (Currently Amended) The compound according to claim 23, wherein X is selected from O[[,]] and S[[and NH]].

Claims 25-27. (Canceled)

28. (Original) The compound according to claim 19, wherein the C_6 aryl groups of R^3 are independently selected from those derived from benzene and heteroaryl groups, where the heteroatom or heteroatoms are nitrogen.

29. (Original) The compound according to claim 28, wherein the C_6 aryl groups of R^3 are independently selected from those derived from benzene, pyridine and 1,3-pyrimidine.

30. (Original) The compound according to claim 19, wherein A is a single bond.

31. (Original) The compound according to claim 19, wherein A is a C_{1-3} alkylene group.

32. (Original) The compound according to claim 19, wherein R^5 is either:

(i) a group of formula (II) :



(II)

; or

(ii) a group of formula (III) :



(III)

33. (Original) The compound according to claim 32, wherein R is selected from an optionally substituted C_{5-20} aryl group, and an optionally substituted C_{5-20} aryl C_{1-7} alkyl group.

34. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a pharmaceutical composition of claim 18.

35. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 19.

36. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 20.

37. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 21.

38. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 22.

39. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 23.

40. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 24.

41. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 28.

42. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 29.

43. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 30.

44. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 31.

45. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 32.

46. (new) A method of treating a primary headache disorder by antagonism of an EP4 receptor, which method comprises administering to a patient in need of said treating a compound of claim 33.

47. (new) A compound of formula (I):



(I)

or a salt, solvate and chemically protected form thereof, wherein:

R^2 is selected from H, methyl, CF_3 or iso-propyl;

Y is $-CH_2-X-$ and X is O or S;

R^3 is an optionally substituted C_6 aryl group linked to a further optionally substituted C_6 aryl group and wherein the said C_6 aryl groups are independently selected from those derived from benzene and heteroaryl groups, where the heteroatom or heteroatoms are nitrogen and wherein if both C_6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings;

A is a single bond or a C_{1-3} alkylene group; and

R^5 is either:

(i) carboxy;

(ii) a group of formula (**II**):



(**II**)

; or

(iii) a group of formula (**III**):



(**III**)

,

wherein R is optionally substituted C_{1-7} alkyl, C_{5-20} aryl or $NR^{N3}R^{N4}$, where R^{N3} and R^{N4} are independently selected from optionally substituted C_{1-4} alkyl;

(iv) tetrazol-5-yl,

Wherein the substitution on the C_6 aryls of R^3 is selected from the group consisting of $-CH_3$, $-CF_3$ $-CH_2OH$, -OMe $-OCF_3$ -OEt $-OCHF_2$ -SMe, $-NMe_2$, F, Cl, -CN, -O-CH2-O- and -C(=O)Me

except that when R^2 is methyl, Y is $-CH_2$-O- and R^5 is carboxy or C_{1-7} alkyl ester thereof, then R^3 is not:

(i)  ; or

(ii) 

48. (new) A compound of formula (**I**):



(**I**)

or a salt, solvate and chemically protected form thereof, wherein:

R^2 is methyl

Y is $-(CH)_n$-X- wherein n is 1 or 2 and X is O or S;

R^3 is an optionally substituted C_6 aryl group linked to a further optionally substituted C_6 aryl group and wherein the said C_6 aryl groups are independently selected from those derived from benzene pyridine and 1,3-pyrimidine and wherein if both C_6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings;

A is a single bond or a C_{1-3} alkylene group; and

R^5 is either:

(i) a group of formula (**II**):



(**II**)

; or

(ii) a group of formula (**III**):



(III)

,

wherein R is optionally substituted C_{5-20} aryl group or an optionally substituted C_{5-20} aryl-C_{1-7} alkyl group

Wherein the substitution on the C_6 aryls of R^3 is selected from the group consisting of -CH_3, -CF_3 -CH_2OH, -OMe -OCF_3 -OEt -$OCHF_2$ -SMe, -NMe_2, F, Cl, -CN, -O-CH2-O- and -C(=O)Me, and

wherein the C_{5-20} aryl group and C_{5-20} aryl-C_{1-7} alkyl groups of R are optionally substituted by C_{1-4} alkyl

49. (new) A compound of formula (**I**):



(I)

or a salt, solvate and chemically protected form thereof, wherein:

R^2 is methyl;

Y is –CH_2-X- and X is O or S;

R^3 is an optionally substituted C_6 aryl group linked to a further optionally substituted C_6 aryl group wherein one of the said C_6 aryl groups is derived from benzene and the other from pyridine or 1,3-pyrimidine;

A is a single bond or a C_{1-3} alkylene group; and

R^5 is either:

(i) a group of formula (**II**):



(II)

; or

(ii) a group of formula (**III**):



(III)

,

wherein R is optionally substituted C_{5-20} aryl group, and an optionally substituted C_{5-20} aryl-C_{1-7} alkyl group

Wherein the substitution on the C_6 aryls of R^3 is selected from the group consisting of -CH_3, -CF_3 -CH_2OH, -OMe -OCF_3 -OEt -$OCHF_2$ -SMe, -NMe_2, F, Cl, -CN, -O-CH2-O- and -C(=O)Me, and

wherein the C_{5-20} aryl group and C_{5-20} aryl-C_{1-7} alkyl groups of R are optionally substituted by C_{1-4} alkyl.

50. (new) A compound of formula (**I**):



(I)

or a salt, solvate and chemically protected form thereof, wherein:

R^2 methyl;

Y is $-CH_2-O-$;

R^3 is an optionally substituted C_6 aryl group linked to a substituted C_6 aryl group wherein one of the said C_6 aryl groups is derived from benzene and the other from pyridine and wherein only the ring not bound to Y is substituted;

A is a single bond or a C_{1-3} alkylene group; and

R^5 is a group of formula (II):



(II)

Wherein the substitution on the C_6 aryls of R^3 is selected from the group consisting of $-CH_3$, $-CF_3$ $-CH_2OH$, -OMe $-OCF_3$ -OEt $-OCHF_2$ -SMe, $-NMe_2$, F, Cl, -CN, -O-CH2-O- and -C(=O)Me, and

wherein the C_{5-20} aryl group and C_{5-20} aryl-C_{1-7} alkyl groups of R are optionally substituted by C_{1-4} alkyl

51. (new) A compound of formula (I):



(I)

or a salt, solvate and chemically protected form thereof, wherein:

R^2 methyl;

Y is $-CH_2-X-$ where X is O or S;

R^3 is an optionally substituted C_6 aryl group linked to a further optionally substituted C_6 aryl group wherein one of the said C_6 aryl groups is derived from benzene and the other from pyridine the pyridine derived group being furthest from the furan core and wherein only the ring not bound to Y is substituted;

A is a single bond; and

R^5 is a group of formula (**II**):



(II)

Wherein the substitution on the substituted C_6 aryl of R^3 is selected from the group consisting of $-CH_3$, $-CF_3$ $-CH_2OH$, -OMe $-OCF_3$ -OEt $-OCHF_2$ -SMe, $-NMe_2$, F, Cl, -CN, -O-CH2-O- and -C(=O)Me, and

wherein the C_{5-20} aryl group and C_{5-20} aryl-C_{1-7} alkyl groups of R are optionally substituted by C_{1-4} alkyl.

52. (new) A compound of formula (**I**):



(I)

or a salt, solvate and chemically protected form thereof, wherein:

R^2 methyl;

Y is $-CH_2-O-$;

R^3 is an optionally substituted C_6 aryl group linked to a further optionally substituted C_6 aryl group wherein one of the said C_6 aryl groups is derived from benzene and the other from pyridine and wherein only the ring not bound to Y is substituted;

A is a single bond; and

R^5 is a group of formula **(II)**:



(II)

Wherein the substitution on the substituted C_6 aryl of R^3 is selected from the group consisting of $-CH_3$, $-CF_3$ $-CH_2OH$, -OMe $-OCF_3$ -OEt $-OCHF_2$ -SMe, $-NMe_2$, F, Cl, -CN, -O-CH2-O- and -C(=O)Me, and

wherein the C_{5-20} aryl group and C_{5-20} aryl-C_{1-7} alkyl groups of R are optionally substituted by C_{1-4} alkyl.